Document Detail

Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA--a manifestation of the basic disease or the treatment.
MedLine Citation:
PMID:  11042521     Owner:  NLM     Status:  MEDLINE    
All-trans-retinoic acid (ATRA) is considered the recommended induction treatment for acute promyelocytic leukemia. In the pre-ATRA era pulmonary bleeding was a common cause of death in these patients, mostly due to disseminated intravascular coagulation which was further exacerbated by the administration of chemotherapy. Although ATRA syndrome, the most serious adverse effect of ATRA treatment, involves the lungs, pulmonary hemorrhage has only rarely been reported as a manifestation of ATRA syndrome. Here we describe 2 patients who developed diffuse alveolar hemorrhage during treatment with ATRA. The possible mechanisms of pulmonary bleeding in these cases are discussed.
P Raanani; E Segal; I Levi; M Bercowicz; H Berkenstat; A Avigdor; A Perel; I Ben-Bassat
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Leukemia & lymphoma     Volume:  37     ISSN:  1042-8194     ISO Abbreviation:  Leuk. Lymphoma     Publication Date:  2000 May 
Date Detail:
Created Date:  2001-01-26     Completed Date:  2003-06-23     Revised Date:  2006-04-24    
Medline Journal Info:
Nlm Unique ID:  9007422     Medline TA:  Leuk Lymphoma     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  605-10     Citation Subset:  IM    
Institute of Hematology, The Chaim Sheba Medical Center and Sackler School of Medicine, Tel-Aviv University, Tel-Hashomer, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects*,  therapeutic use
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Blood Coagulation Tests
Cytarabine / administration & dosage
Daunorubicin / administration & dosage
Dyspnea / chemically induced
Fatal Outcome
Fever / chemically induced
Hemorrhage / chemically induced,  etiology*
Leukemia, Promyelocytic, Acute / complications,  drug therapy*
Lung Diseases / chemically induced,  etiology*
Middle Aged
Pulmonary Alveoli / drug effects
Remission Induction
Tretinoin / administration & dosage,  adverse effects*,  therapeutic use
Reg. No./Substance:
0/Antineoplastic Agents; 147-94-4/Cytarabine; 20830-81-3/Daunorubicin; 302-79-4/Tretinoin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Epstein-Barr virus (EBV)-induced B-cell proliferative disorder after chemotherapy in a patient with ...
Next Document:  Chronic myelomonocytic leukemia derived from a possible common progenitor of monocytes and natural k...